☆ 4.7 Article

Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

CLINICAL CANCER RESEARCH (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

Pedro Rocha et al.

Summary: The study revealed an association between CD73 expression levels in LUAD with immune infiltration and PD-L1 protein expression, with tumors showing higher CD73 expression exhibiting augmented immune response. Further exploration of the role of CD73 in immunotherapeutic response of LUAD is warranted based on our findings.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

Xiuning Le et al.

Summary: EGFR-mutant non-small cell lung cancer exhibits an immune-inert phenotype, with the CD73/adenosine pathway identified as a potential therapeutic target for treatment enhancement.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Kevin Litchfield et al.

Summary: Checkpoint inhibitors (CPIs) enhance adaptive immunity, with clonal tumor mutation burden (TMB) identified as the strongest predictor of CPI response. Dinucleotide variants may serve as a source of immunogenic epitopes, while copy-number alterations and HLA evolutionary divergence lack pan-cancer significance.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

Add to Collection

Review Oncology

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah Blythe Doroshow et al.

Summary: PD-L1 expression is currently the best predictor of responsiveness to immune-checkpoint inhibitors, despite challenges in clinical use such as variability in different assays and cut-off points, as well as the lack of prospective comparisons with clinical outcomes. Nevertheless, several immunohistochemical assays have been approved for clinical use, with implications for pathology services and potential impacts on clinical outcomes. Comparison of FDA-approved PD-L1 assays, understanding of the varying implications of PD-L1 expression across different tumour types, and exploration of novel approaches to optimize its clinical utility are important topics for further research and practice.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

J. Lee et al.

Journal of Thoracic Oncology (2021)

Add to Collection

Article Oncology

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Nasser K. Altorki et al.

Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.

LANCET ONCOLOGY (2021)

Add to Collection

Review Oncology

Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer

Jamie E. Chaft et al.

Summary: The treatment goal for early-stage lung cancer patients is cure, with surgical resection or radiotherapy as definitive local treatments along with adjuvant therapy to improve the likelihood of cure. New therapies lag behind due to inefficient trial designs and lengthy follow-ups, despite efforts to study surrogate endpoints to shorten trial durations.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

Hitoshi Dejima et al.

Summary: The evolution of immune landscape in lung adenocarcinoma involves a gradual increase of immunosuppression and decrease of anti-tumor response associated with specific genomic and epigenetic features, influencing the progression from preneoplasia to invasive ADC.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing

Ansam Sinjab et al.

Summary: The study reveals the geospatial evolution of cell populations, states, and transcriptomic features in lung adenocarcinoma (LUAD) from normal regions to tumors. LUAD shows significant intratumor cell heterogeneity and transcriptional lineage-plasticity programs. T regulatory cell phenotypes increase near LUAD, while cytotoxic CD8(+) T cells and other cell types decrease in normal tissues.

CANCER DISCOVERY (2021)

Add to Collection

Meeting Abstract Oncology

Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.

Melba C. Jaramillo et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

Luis G. Paz-Ares et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Jonathan Spicer et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells

Maria Casanova-Acebes et al.

Summary: Macrophages play a crucial role in shaping the tumor microenvironment and tumor immunity, with tissue-resident macrophages identified as key contributors to early lung cancer progression. Targeting tissue-resident macrophages may offer new possibilities for prevention and treatment of early lung cancer lesions.

NATURE (2021)

Add to Collection

Review Oncology

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Michael J. Grant et al.

Summary: The treatment landscape of driver-negative non-small-cell lung cancer is rapidly changing due to the efficacy of immune-checkpoint inhibitors targeting PD-1 or PD-L1 as first-line therapy. Histological subtype and PD-L1 expression levels are crucial factors in regimen selection for patients, with emerging biomarkers and novel strategies potentially refining treatment paradigms in the future. Immune-checkpoint inhibitors are now standard-of-care therapies for patients with advanced-stage NSCLC, with various approved regimens available, highlighting the need for further research to optimize outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

PD-L1 regulation revisited: impact on immunotherapeutic strategies

Giulia Lucibello et al.

Summary: This review examines the pathways involved in PD-L1 expression and the druggable strategies being developed to enhance treatment response and prevent resistance in cancer patients. These new strategies will pave the way for effective treatment combinations in future oncology clinical trials.

TRENDS IN MOLECULAR MEDICINE (2021)

Add to Collection

Article Immunology

Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer

Enrico Munari et al.

Summary: This study aimed to clarify the significance and impact of PD-L1 and PD-1 expression on the prognostic value of CD8(+) tumor infiltrating lymphocytes in patients with primary resected non-small cell lung cancer. The results showed a strong prognostic value of CD8(+) cells, especially in PD-L1 negative tumors lacking PD-1(+) TILs, and the importance of assessing and quantifying the immune contexture in cancer for prognostic and possibly predictive purposes.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Ben Sidders et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Review Oncology

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

William D. Travis et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Shugeng Gao et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Sohyun Hwang et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Oncology

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Learning from clinical trials of neoadjuvant checkpoint blockade

Judith M. Versluis et al.

NATURE MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Geospatial immune variability illuminates differential evolution of lung adenocarcinoma

Khalid AbdulJabbar et al.

NATURE MEDICINE (2020)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Nick van Dijk et al.

NATURE MEDICINE (2020)

Add to Collection

Review Oncology

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Daniela Bruni et al.

NATURE REVIEWS CANCER (2020)

Add to Collection

Article Multidisciplinary Sciences

Immune evasion before tumour invasion in early lung squamous carcinogenesis

Celine Mascaux et al.

NATURE (2019)

Add to Collection

Editorial Material Oncology

A reality check of the accelerated approval of immune-checkpoint inhibitors

Jennifer Gill et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Review Immunology

Macrophages as regulators of tumour immunity and immunotherapy

David G. DeNardo et al.

NATURE REVIEWS IMMUNOLOGY (2019)

Add to Collection

Article Medicine, Research & Experimental

Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC

Julia Kargl et al.

JCI INSIGHT (2019)

Add to Collection

Article Medicine, Research & Experimental

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression

Haidong Tang et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Add to Collection

Article Medicine, Research & Experimental

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression

Heng Lin et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Add to Collection

Article Oncology

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Scott Gettinger et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott et al.

NATURE MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang et al.

NATURE MEDICINE (2018)

Add to Collection

Article Oncology

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

H. Kadara et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Medicine, Research & Experimental

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Add to Collection

Article Immunology

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

Vikram R. Juneja et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

Add to Collection

Article Oncology

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Aleix Prat et al.

CANCER RESEARCH (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Yonit Lavin et al.

CELL (2017)

Add to Collection

Article Oncology

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients

Edwin R. Parra et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Review Oncology

Classifying Cancers Based on T-cell Infiltration and PD-L1

Michele W. L. Teng et al.

CANCER RESEARCH (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

Michael S. Rooney et al.

CELL (2015)

Add to Collection

Review Biotechnology & Applied Microbiology

Combination cancer immunotherapy and new immunomodulatory targets

Kathleen M. Mahoney et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection

Article Multidisciplinary Sciences

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst et al.

NATURE (2014)

Add to Collection

Article Medicine, General & Internal

Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer

Timothy R. Church et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Oncology

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

Apar Pataer et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer

Robert Timmerman et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)

Add to Collection

Article Oncology

An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer

Paul Roepman et al.

CLINICAL CANCER RESEARCH (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.